ROYALTY PHARMA Aktie

>ROYALTY PHARMA Aktienkurs

42.16 EUR +0.7% (TradegateBSX)

Ask: 42.18 EUR / 290 Stück

Bid: 42.01 EUR / 290 Stück

Tagesumsatz: 68 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>ROYALTY PHARMA Performance

1 Woche: +3,2%

1 Monat: +2,9%

3 Monate: +28,3%

6 Monate: +35,9%

1 Jahr: +48,8%

laufendes Jahr: +26,4%

>ROYALTY PHARMA Aktie

Name:

ROYALTY PHARMA OA DL-0001

Land:

Großbritannien

Sektor:

Gesundheit

ISIN/ Wkn:

GB00BMVP7Y09 / A2P62D

Symbol/ Ticker:

RPD (Frankfurt) / RPRX (NASDAQ)

Kürzel:

FRA:RPD, ETR:RPD, RPD:GR, NASDAQ:RPRX

Index:

Webseite:

https://www.royaltypharma..

Profil:

Royalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and develo..
>Volltext..

Marktkapitalisierung:

24234.46 Mio. EUR

Unternehmenswert:

34078.82 Mio. EUR

Umsatz:

2060.27 Mio. EUR

EBITDA:

1352.85 Mio. EUR

Nettogewinn:

667.71 Mio. EUR

Gewinn je Aktie:

1.55 EUR

Schulden:

7768.26 Mio. EUR

Liquide Mittel:

535.99 Mio. EUR

Operativer Cashflow:

2248.06 Mio. EUR

Bargeldquote:

Umsatzwachstum:

-7.41%

Gewinnwachstum:

-20.89%

Dividende je Aktie:

0.77 EUR

Dividendenrendite:

1.93%

Dividendenschätzung:

2.02%

Div. Historie:

20.02.26 - 0.1993975€
14.11.25 - 0.189244€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.583.989 USD.

Suchwörter:

ROYALTY PHARMA

Letzte Datenerhebung:

04.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 428.42 Mio. St.

Frei handelbar: 92.65%

Leerverk. Aktien: 2.7%

Rückkaufquote: 4.39%

Mitarbeiter: 100

Umsatz/Mitarb.: 20.6 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 5.86%

Bewertung:

KGV: 27.7

KGV lG: 9.98

KUV: 8.7

KBV: 3.26

PEG-Ratio: -

EV/EBITDA: 25.19

Rentabilität:

Bruttomarge: -

Gewinnmarge: 32.41%

Operative Marge: 65.56%

Managementeffizenz:

Gesamtkaprendite: 4.07%

Eigenkaprendite: 11.48%

>Peer Group

Gesundheit, Multiple Sklerose- Behandlung, Neurologische- & psychische Behandlung/ Medizin, Onkologie/ Krebs- Behandlung

>ROYALTY PHARMA Chart & Kurs - NASDAQ

>ROYALTY PHARMA News

30.03.26 - 14:12	Royalty Pharma, Johnson & Johnson Enter Co-funding Agreement To Advance Development Of JNJ-4804 (AFX)
	NEW BRUNSWICK (dpa-AFX) - Royalty Pharma plc (RPRX) announced a research and development co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the dev......

30.03.26 - 13:48	Royalty Pharma in $500M R&D funding collaboration with J&J (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.03.26 - 13:18	Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases (GlobeNewswire EN)
	NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases....

26.03.26 - 03:01	Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1583989 USD (Insiderkauf)
	Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2026-03-23...

23.03.26 - 12:18	Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence (GlobeNewswire EN)
	NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma....

17.03.26 - 21:03	Royalty Pharma Announces Expansion of Leadership Team (GlobeNewswire EN)
	Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments Greg Butz joins Royalty Pharma as Executive Vice President, Partnering & Investments...

05.03.26 - 01:01	Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1627534 USD (Insiderkauf)
	Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2026-03-02...

04.03.26 - 07:48	Royalty Pharma auf der TD Cowen Konferenz: Einblicke in die Wachstumsstrategie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 13:03	Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma′s Global Platform (GlobeNewswire EN)
	NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking....

02.03.26 - 12:42	Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma (AFX)
	WASHINGTON (dpa-AFX) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of......

02.03.26 - 12:12

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing (GlobeNewswire EN)

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne)....

02.03.26 - 12:03

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing (GlobeNewswire EN)

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne)....

26.02.26 - 22:18	Royalty Pharma to Present at TD Cowen′s 46th Annual Health Care Conference (GlobeNewswire EN)
	NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET....

26.02.26 - 02:01	Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1576606 USD (Insiderkauf)
	Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2026-02-23...

11.02.26 - 22:48	Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 16:45	Here′s What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings (Zacks)
	While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

11.02.26 - 15:36	Royalty Pharma (RPRX) Q4 2025 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

11.02.26 - 13:42	Royalty Pharma Plc Bottom Line Advances In Q4 (AFX)
	WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced earnings for its fourth quarter that Increased from the same period last yearThe company's earnings totaled $214 million. This compares w......

10.02.26 - 15:57	Royalty Pharma Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 03:02	Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 4924997 USD (Insiderkauf)
	Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2026-02-03...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram